Manager, Screening & Compound Management at Axsome Therapeutics Inc

Bridgewater, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceutical, Drug DiscoveryIndustries

Requirements

Expertise in optimizing high-throughput screening robotic platforms and compound operations
Knowledge of executing high-quality biochemical and cell-based assays
Proficiency in compound handling, storage, screening, and maintaining integrity of compound libraries
Experience with advanced technologies such as automated liquid handling systems and data analytics tools
Ability to engage in strategic planning, resource allocation, and prioritizing screening campaigns
Skills in acquiring new chemical entities and developing specialized protocols
Capability to collaborate with cross-functional teams in medicinal chemistry, biology, and informatics
Leadership skills to lead and mentor a multidisciplinary team of scientists and technicians
Adherence to relevant regulatory requirements and company Standard Operating Procedures (SOPs)
Ability to anticipate challenges, troubleshoot technical issues, and adapt strategies
Proficiency in providing detailed reports and analyses of screening outcomes

Responsibilities

Lead the strategic planning and execution of high-throughput screening campaigns, aligning with organizational goals and project timelines
Collaborate with cross-functional teams to design robust screening workflows, optimize assay conditions, and implement cutting-edge technologies
Anticipate challenges, troubleshoot technical issues, and adapt strategies to maintain efficiency and reliability of screening operations
Provide detailed reports and analyses of screening outcomes, communicating findings to stakeholders and integrating into research initiatives
Oversee the management of the compound library, implementing advanced inventory management systems and quality control protocols
Work with medicinal chemistry teams to expand the library with diverse and high-value compounds, maintaining compliance with regulatory and safety standards
Develop strategies to optimize compound storage conditions and ensure long-term stability
Interact with multidisciplinary team, providing mentorship, performance feedback, and professional growth opportunities
Drive continuous improvement initiatives to enhance efficiency and impact of screening and compound management processes
Establish key performance indicators (KPIs) to measure process effectiveness and identify optimization areas

Skills

High-Throughput Screening

Compound Management

Biochemical Assays

Cell-Based Assays

Automated Liquid Handling

Data Analytics

Medicinal Chemistry

Robotics

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free